In a nutshell This study examined whether adding mitoxantrone (Novantrone) to the treatment combination known as FCR improves outcomes for chronic lymphocytic leukemia (CLL). Researchers reported no significant benefit when mitoxantrone was added to FCR. Some background For physically fit CLL patients, the chemotherapy and immunotherapy...
Read More
In a nutshell This study examined treatment outcomes in patients with blast-phase chronic myeloid leukemia (CML). Authors reported that intensive treatment early followed by stem cell transplantation remains as the most effective approach. Certain patient characteristics and treatment history are significant predictors of outcomes. Some...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness a combination of ibrutinib (Imbruvica) and rituximab (Rituxan) with hyper-CVAD and MTX-AraC chemotherapy in treating mantle cell lymphoma (a cancer of B-cells). The primary outcome will be measured by overall response and side effects. This trial is taking place at the University...
Read MoreIn a nutshell This phase 2 clinical trial will test the safety and effectiveness of an ibrutinib (Imbruvica) and fludarabine (Fludara) treatment in patients with previously untreated chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the safety and effectiveness of the treatment. The details Ibrutinib is a drug that...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of ibrutinib (Imbruvica) with venetoclax (Venclexta) in treating patients with chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the response to treatment. This trial is being conducted at the University of Texas MD Anderson Cancer Center in Houston,...
Read More
In a nutshell This phase 2 clinical trial will test the effectiveness of bendamustine (Treanda) and rituximab (Rituxan) induction therapy followed by rituximab and lenalidomide (Revlimid) maintenance therapy in patients with previously untreated chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the time to disease progression....
Read MoreIn a nutshell This study aimed to investigate the influence of the time of starting adjuvant chemotherapy on survival outcomes in different types of breast cancer. This study concluded that more aggressive breast cancers require early adjuvant chemotherapy. Some background Surgery to remove the tumor is a commonly used treatment method for...
Read More
In a nutshell This study aimed to investigate the long-term effectiveness of oncoplastic surgery in treating breast cancer patients. This study concluded oncoplastic surgery was efficient and could be used instead of a mastectomy in treating breast cancer patients. Some background Breast conserving surgery (BCS) is used with radiotherapy...
Read More
In a nutshell This phase 2/3 clinical trial will test the effectiveness of gilteritinib (ASP2215) with or without azacitidine (Vidaza) versus azacitidine alone in treating newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutation. The primary outcome will be measured by the overall survival. The details ASP2215 is is an...
Read MoreIn a nutshell This study aimed to identify ways to predict long-term outcomes of stem cell transplants for children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This study concluded that factors such as age, age and disease status at time of transplant and presence of chronic GVHD influenced the risk score for acute...
Read More
In a nutshell This study reviewed evidence on the use of targeted therapies for chronic lymphocytic leukemia (CLL). Authors concluded that newly developed targeted therapies are an effective treatment option for CLL, including CLL that is difficult to treat. Some background Standard therapy for CLL usually involves a combination of chemotherapies...
Read More
In a nutshell This study looks at the outcomes for patients over 80 years old who have diffuse large B-cell lymphoma. The study concluded that patients over 80 had significantly better outcomes when treated with rituximab and anthracycline-based chemotherapy, such as the R-CHOP treatment. Some background Diffuse large B-cell lymphoma (DLBCL)...
Read More
